跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
1-A-46
首页
药物
1-A-46
1-A-46
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS
EP 4551224 A4
申请人: ANTECIP BIOVENTURES II LLC
优先权: 2022
CN
EP
US
WO
26 件公开
EP 4766443 A1
申请人: ANTECIP BIOVENTURES II LLC
优先权: 2023
CN
EP
WO
3 件公开
EP 4777092 A1
申请人: ANTECIP BIOVENTURES II LLC
优先权: 2023
CN
EP
WO
3 件公开
US 20250064797 A1
申请人: ANTECIP BIOVENTURES II LLC
优先权: 2024
US
2 件公开
US 20250114348 A1
申请人: ANTECIP BIOVENTURES II LLC
优先权: 2024
US
WO 2026097042 A1
申请人: ANTECIP BIOVENTURES II LLC
优先权: 2024
WO
Humanised antibodies
US 7241877 B2
申请人: CELLTECH R&D LTD
优先权: 2003
US
14 件公开
US RE48787 E
申请人: UCB BIOPHARMA SRL
优先权: 2001
US
2 件公开
Oncoprotein protein kinase
US 2006121527 A1
申请人: UNIV CALIFORNIA
优先权: 2001
US
9 件公开
US 2005170381 A1
申请人: UNIV MASSACHUSETTS MEDICAL
优先权: 2001
US
4 件公开
Anti-CLDN antibody and pharmaceutical composition thereof and detection method therefor
US 12692309 B2
申请人: QURE BIOTECHNOLOGY SHANGHAI CO LTD
优先权: 2019
CN
EP
US
WO
7 件公开
TREATMENT OF DEPRESSION
EP 4373480 A1
申请人: ANTECIP BIOVENTURES II LLC
优先权: 2021
CN
EP
US
WO
7 件公开
EP 4525871 A4
申请人: ANTECIP BIOVENTURES II LLC
优先权: 2022
CN
EP
US
WO
4 件公开
BUPROPION AS A MODULATOR OF DRUG ACTIVITY
EP 4626429 A1
申请人: ANTECIP BIOVENTURES II LLC
优先权: 2022
CN
EP
US
WO
6 件公开
Oxabispidine compounds useful in the treatment of cardiac arrhythmias
US 7164017 B2
申请人: ASTRAZENECA AB
优先权: 1999
CN
US
6 件公开
Oxabispidine compounds and their use in the treatment of cardiac arrhythmias
US 7354917 B2
申请人: ASTRAZENECA AB
优先权: 2004
CN
US
6 件公开
SEPARATED ANTIGEN AXL BINDING PROTEIN AND USE THEREOF
EP 4067384 A1
申请人: SUMGEN MAB BEIJING BIOTECH CO LTD
优先权: 2019
CN
EP
US
WO
5 件公开
Scaffold proteins
US 11952415 B2
申请人: AVACTA LIFE SCIENCES LTD
优先权: 2017
CN
EP
US
5 件公开
第 1 / 9 页
上一页
下一页
药物
反馈